Back to top
more

Amedisys (AMED)

(Real Time Quote from BATS)

$96.65 USD

96.65
470,232

-0.15 (-0.16%)

Updated Nov 8, 2024 03:55 PM ET

After-Market: $96.71 +0.06 (0.06%) 4:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Awantika Poddar headshot

5 Mid-Cap Stocks For Growth Investors to Buy Right Now

Investing in mid-cap companies is a safe bet, especially during economic downturns and stringent credit conditions.

    Sweta Killa headshot

    5 Growth Stocks at New Highs with Room for More Upside

    We have highlighted five growth stocks that hit all-time highs in the current market rally and will likely to continue to move higher given their superior fundamentals.

      Here's Why You Should Add Amedisys (AMED) to Your Portfolio

      Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.

        Will Strong RTG Arm Shape Medtronic's (MDT) Q1 Earnings?

        Medtronic (MDT) poised to gain on continued growth in RTG business in Q1.

          Will Solid Diabetes Arm Drive Medtronic's (MDT) Q1 Earnings?

          Medtronic (MDT) poised to gain on strength in Diabetes business in Q1 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.

            Haemonetics Strong on Plasma Unit Amid Blood Center Weakness

            Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.

              Hologic Launches Fluent Fluid Management System, Widens Suite

              Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.

                Amedisys (AMED) Shares March Higher, Can It Continue?

                As of late, it has definitely been a great time to be an investor in Amedisys, Inc. (AMED).

                  Amedisys (AMED) Grows on Robust Home Health, Personal Care

                  Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.

                    Here's Why You Should Invest in Align Technology (ALGN) Now

                    We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.

                      Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm

                      Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.

                        Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips

                        At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.

                          Hill-Rom (HRC) Q3 Earnings Top Estimates, Margins Expand

                          Hill-Rom (HRC) registers a solid year-over-year revenue rise on strong domestic growth, driven by a robust performance at Patient Support Systems and Surgical Solutions.

                            Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop

                            The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.

                              GNC Holdings (GNC) Q2 Earnings Beat, Revenues Miss Mark

                              Though GNC Holdings' (GNC) domestic retail comps are slightly weaker than expected, the company performs strongly in e-commerce business and at International segment.

                                Integra (IART) Reports In-Line Q2 Earnings, Tapers View

                                Integra LifeSciences' (IART) balanced segmental revenue growth in Q2 is encouraging.

                                  Align Technology (ALGN) Beats on Earnings and Revenues in Q2

                                  Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q2.

                                    Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised

                                    Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.

                                      Zacks.com highlights: HollyFrontier, Amedisys, MGM Growth Properties, Louisiana-Pacific and Houlihan Lokey

                                      Zacks.com highlights: HollyFrontier, Amedisys, MGM Growth Properties, Louisiana-Pacific and Houlihan Lokey

                                        Bet on These 5 Low Leverage Stocks for Safe Returns

                                        As we are off to a strong start in the Q2 earnings season, blindly pursuing high earnings yielding stocks might drain all your money before you know, if the stock bears a high debt-to-equity ratio.

                                          Nalak Das headshot

                                          Weekly Jobless Claims Plunge to 48-Year Low: 5 Top Picks

                                          Job additions continued to be substantial in June, indicating that hiring remains robust even as the economy nears full employment.

                                            4 Reasons to Add Anadarko Petroleum (APC) to Your Portfolio

                                            Anadarko Petroleum (APC) seems a lucrative choice, promising better returns for investors on the back of four factors.

                                              The Zacks Analyst Blog Highlights: Korn/Ferry International, Avis Budget Group, Regal Beloit, Amedisys and Jacobs Engineering Group

                                              The Zacks Analyst Blog Highlights: Korn/Ferry International, Avis Budget Group, Regal Beloit, Amedisys and Jacobs Engineering Group

                                                Outpatient & Home Healthcare Stock Outlook: Prospects Bright

                                                The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.

                                                  Swarup Gupta headshot

                                                  Profit From Strong Job Additions With These 5 Top-Ranked Picks

                                                  June's jobs report indicates that corporations are successfully filling up open positions even as the pool of skilled workers continues to shrink.